Reduced risk of shunt revision with adjustable valves: a population-based cohort study over three decades
Acta Neurochirurgica · 03.02.2026 · 168 (1)
DOI: 10.1007/s00701-026-06786-7 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Neurochirurgica, online erschienen am 03.02.2026. Verfasst von Siiri Oksa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, 70211, Finland. siioksa@uef.fi. Hauptthemen laut MEDLINE: Reoperation, Hydrocephalus, Normal Pressure, Ventriculoperitoneal Shunt, Postoperative Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kuopio University Hospital VTR Fund, Research Council of Finland, Alzheimer's Association.
Abstract (Originalsprache)
Background
Idiopathic normal pressure hydrocephalus (iNPH) is a neurological disease characterized by ventriculomegaly and Hakim’s triad. At present, symptoms can be alleviated only by cerebrospinal fluid (CSF) shunt surgery. Yet, various complications after shunting may occur, occasionally requiring repeated shunt revisions. In this retrospective, population-based study, our objective was to compare revision rates and causes for revision surgeries between adjustable shunt valve and fixed-pressure valves in iNPH patients.
Methods
Altogether 1220 patients were evaluated for possible iNPH at Kuopio University Hospital between 1991 and 2023. Probable iNPH was diagnosed in 809 patients who received their first ventriculoperitoneal shunt (VPS). Of the patient cohort, 566 were shunted using an adjustable valve (2008–2023) and 243 received a fixed pressure valve (1991–2012). Hospital records and nationwide registries were used to construct a timeline for each patient from the shunt insertion and until death ( n = 430) or the end of 2023.
Results
Overall revision rate was lower in iNPH patients receiving an adjustable valve (14% vs. 30%, p < .001, 95% CI 0.27—0.56). The incidence of multiple revisions was also lower in the adjustable valve group (27% vs. 32% p = 0.002, 95% CI 0.21—0.71). The most common cause for revision was peritoneal catheter malposition in the adjustable valve group (44%) and shunt underdrainage in the fixed-pressure valve group (25%).
Conclusions
Adjustable shunt valves have decreased the need for shunt revision surgeries due to under- and overdrainage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, 70211, Finland. siioksa@uef.fi.
- Department of Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, 70211, Finland.
- Institute of Biomedicine, University of Eastern Finland, Kuopio, 70211, Finland.
- Department of Neurosurgery, Kuopio University Hospital, Kuopio, 70210, Finland.
Förderung
- Kuopio University Hospital VTR Fund
- Research Council of Finland
- Alzheimer's Association
- Sigrid Juséliuksen Säätiö
- Strategic Neuroscience Funding of the University of Eastern Finland
- University of Eastern Finland
Zitieren
APA
Oksa, S., Kasurinen, R., Lipponen, A., Leinonen, V., & Luikku, A. J. (2026). Reduced risk of shunt revision with adjustable valves: a population-based cohort study over three decades. Acta Neurochirurgica, 168(1). https://doi.org/10.1007/s00701-026-06786-7
Vancouver
Oksa S, Kasurinen R, Lipponen A, Leinonen V, Luikku AJ. Reduced risk of shunt revision with adjustable valves: a population-based cohort study over three decades. Acta Neurochirurgica. 2026;168(1). doi:10.1007/s00701-026-06786-7
BibTeX
@article{Oksa2026,
author = {Oksa, Siiri and Kasurinen, Roosa and Lipponen, Anssi and Leinonen, Ville and Luikku, Antti J},
title = {Reduced risk of shunt revision with adjustable valves: a population-based cohort study over three decades},
journal = {Acta Neurochirurgica},
year = {2026},
volume = {168},
number = {1},
doi = {10.1007/s00701-026-06786-7}
}
EUVIMED